Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CSI-Glucagon for Congenital Hyperinsulinism
NCT02937558Phase 2Completed
- Sponsor
- Xeris Biopharma Holdings, Inc.
- Start
- Oct 2016
- Primary completion
- Sep 2018
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of glucagon in congenital hyperinsulinism (HI) (2 arms), sponsored by Xeris Biopharma Holdings, Inc. Primary endpoint: Number of Subjects With Clinically Meaningful Reduction in Glucose Infusion Rate at 48 hours. Started Oct 2016; status: completed.
02
Drugs
glucagon
03
Conditions
congenital hyperinsulinism (HI)
Beyond the preview
Go deeper on NCT02937558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02937558.